• Organizations: Azura Ophthalmics
Azura gets positive FDA feedback on NDA submission for MGD ointment
Pipeline

Azura gets positive FDA feedback on NDA submission for MGD ointment

Positive pre-NDA meeting for selenium sulfide ointment precedes planned phase 3 data release in Q1 2026 and regulatory submission in H2 2026. 
First patient enrolled in Azura's phase 3 MGD trial for AZR-MD-001
Pipeline

First patient enrolled in Azura's phase 3 MGD trial for AZR-MD-001

New study on selenium sulfide ointment follows positive phase 2 data supporting its ability to target the pathophysiology of MGD.
Azura releases positive data from phase 2 trial of AZR-MD-001 for contact lens discomfort
Pipeline

Azura releases positive data from phase 2 trial of AZR-MD-001 for contact lens discomfort

Latest results on topical ointment support prior phase 2 findings unveiled at AAOPT.
New 6-month data evaluates AZR-MD-001 for MGD
Pipeline

New 6-month data evaluates AZR-MD-001 for MGD

Presented at AAOPT, latest findings follow previous 3-month data evaluating the efficacy of two dosages.
Azura reports positive data from phase 2 trial on AZR-MD-001 for MGD
Pipeline

Azura reports positive data from phase 2 trial on AZR-MD-001 for MGD

Topical ointment’s active ingredient is selenium sulfide, designed with a multi-mechanism of action targeting the pathophysiology of MGD.